CD19 and non-Hodgkin lymphoma: In order to confirm the predictive power of MIP3α, 10 B-ALL patients and 20 B-NHL patients receiving CD19/CD22-redirected CAR-T cell cocktail therapy were assigned to an independent group for validation.